Skip to main content

Envisioning a Transformed Clinical Trials Enterprise in the United States Establishing an Agenda for 2020: Workshop Summary (2012) / Chapter Skim
Currently Skimming:

Appendix A: Workshop Agenda
Pages 85-96

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 85...
... clinical trials that generate medical evidence are becom ing increasingly costly while experiencing greater setbacks. In addition, the shifting "footprint" of clinical trials toward sites outside the United States prompts questions about the generalizability and applicability of the results of those clinical trials to the U.S.
Read the entire page →
From page 86...
... clinical trials enterprise: -- Providing a vision for a clinical trials enterprise in the health care system of 2020. -- Developing a robust clinical trials workforce.
Read the entire page →
From page 87...
... WooD, Session Chair Partner & Managing Director Symphony Capital 9:10 a.m. Presentation of Discussion Paper: The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation robert Califf Director, Duke Translational Medicine Institute Professor of Medicine Vice Chancellor for Clinical and Translational Research Duke University Medical Center Gary filerman President Atlas Health Foundation riCharD murray Vice President, Global Center for Scientific Affairs Office of the Chief Medical Officer Merck & Co., Inc.
Read the entire page →
From page 88...
... alastair J.J. WooD, Panel Moderator Partner & Managing Director Symphony Capital neil Weissman President MedStar Health Research Institute ihor rak Vice President, Clinical Neuroscience AstraZeneca 10:45 a.m.
Read the entire page →
From page 89...
... 1:15 p.m. Presentation of Discussion Paper: Developing a Robust Clinical Trials Workforce robert Califf Director, Duke Translational Medicine Institute Professor of Medicine Vice Chancellor for Clinical and Translational Research Duke University Medical Center elaine Gallin Principal QE Philanthropic Advisors miChael lauer Director, Division of Cardiovascular Sciences National Heart, Lung, and Blood Institute National Institutes of Health
Read the entire page →
From page 90...
... Mayo Professor of Medicine & Epidemiology Mayo Medical School Co-Principal Investigator and Director of Education, Mayo Clinical Center for Translational Scientific Activities (CTSA)
Read the entire page →
From page 91...
... ADJOURN Envisioning a Transformed Clinical Trials Enterprise in the United States: Establishing an Agenda for 2020 NOVEMBER 8, 2011 8:30 a.m. Breakfast available 9:00 a.m.
Read the entire page →
From page 92...
... rubenstein, Session Chair Professor, Department of Medicine, Division of Endocrinology Raymond and Ruth Perelman School of Medicine University of Pennsylvania 9:10 a.m. Presentation of Discussion Paper: Transforming the Economics of Clinical Trials JuDith kramer Associate Professor of Medicine, Duke University Medical Center Executive Director, Clinical Trials Transformation Initiative (CTTI)
Read the entire page →
From page 93...
... ClyDe yanCy, Session Chair Magerstadt Professor of Medicine Chief, Division of Cardiology Feinberg School of Medicine Northwestern University
Read the entire page →
From page 94...
... ClyDe yanCy, Panel Moderator Magerstadt Professor of Medicine Chief, Division of Cardiology Feinberg School of Medicine Northwestern University louis fiore Principal Investigator, VA Cooperative Studies Program Director, VA Cooperative Studies Program Coordinating Center, Boston Department of Veterans Affairs miChael kinG Jolly Senior Vice President Quintiles Innovation
Read the entire page →
From page 95...
... Mayo Professor of Medicine & Epidemiology Mayo Medical School Co-Principal Investigator and Director of Education, Mayo Clinical Center for Translational Scientific Activities (CTSA)
Read the entire page →
From page 96...
... Reflecting on Potential Paths Forward: Setting an Agenda for a Transformed Clinical Trials Enterprise Jean rouleau Scientific Director Institute for Circulatory and Respiratory Health Canadian Institutes of Health Research (CIHR) Jeffrey Drazen, Panel Moderator Editor-in-Chief New England Journal of Medicine DouGlas CroPPer President and Chief Executive Officer Genesis Health System lynn ethereDGe Co-Founder Health Insurance Reform Project and Rapid Learning Project George Washington University ronalD krall Associate Fellow University of Pennsylvania, Center for Bioethics James DoroshoW Director, Division of Cancer Treatment and Diagnosis National Cancer Institute, National Institutes of Health 4:30 p.m.
Read the entire page →

Key Terms

  • trials enterprise
  • transformed clinical
  • trials workforce
  • learning health
  • panel moderator

  • financial incentives
  • clinical center
  • support clinical
  • cal trials
  • translational research

  • session chair
  • sherine gabriel
  • jeffrey drazen
  • care delivery
  • clyde yancy

  • aligning cultural
  • robust clinical
  • effective clinical
  • epidemiology mayo
  • mayo medical

  • effectiveness research
  • cooperative studies
  • studies program
  • health clinical
  • clinical decisions

  • mayo clinical
  • trials transformation
  • clinical neuroscience
  • nih clinical
  • clinical effectiveness


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.